Article
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Clinical and experimental nephrology - 1 Jan 2019
Ito Shuichi, Hidaka Yoshihiko, Inoue Norimitsu, Kaname Shinya, Kato Hideki, Matsumoto Masanori, Miyakawa Yoshitaka, Mizuno Masashi, Okada Hirokazu, Shimono Akihiko, Matsuda Takahisa, Maruyama Shoichi, Fujimura Yoshihiro, Nangaku Masaomi, Kagami Shoji
Abstract excerpt
BACKGROUND: In 2013, eculizumab was approved for treatment of the atypical hemolytic-uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.